Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo
- PMID: 2009918
- DOI: 10.1002/eji.1830210350
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo
Abstract
We have quantitatively studied the effect of interleukin (IL) 2 on the cytotoxic T lymphocyte (CTL) response to tumor cells in vivo. Mastocytoma P815 was transfected with murine IL 2 cDNA (P815-IL 2) and injected into syngeneic mice. The anti-tumor response was analyzed and compared with the response induced by the non-transfected cells. P815 parental cells are highly tumorigenic, causing death within 20-30 days. In contrast, IL 2-transfected cells were totally rejected. Co-injection of IL 2-secreting and parental cells resulted in the inhibition of growth of both type of tumors. In addition, the response induced by IL 2-secreting cells protected the mice against a subsequent challenge with P815. Long-term memory persisted in treated mice 3 months after tumor rejection. Frequencies of CTL precursors and CTL specific for P815 increased as a result of IL 2 secretion by the target cells. Estimates of CTL frequency at days 8 and 12 after injection were 2 to 3 times higher in mice inoculated with P815-IL 2 cells, and this correlated with tumor rejection.
Similar articles
-
Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.Cancer Gene Ther. 2001 May;8(5):321-32. doi: 10.1038/sj.cgt.7700309. Cancer Gene Ther. 2001. PMID: 11477452
-
Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.Eur J Immunol. 1995 Aug;25(8):2340-8. doi: 10.1002/eji.1830250833. Eur J Immunol. 1995. PMID: 7664796
-
Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.Eur J Immunol. 1997 Jul;27(7):1657-62. doi: 10.1002/eji.1830270710. Eur J Immunol. 1997. PMID: 9247574
-
Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.Reg Immunol. 1992 Nov-Dec;4(6):352-62. Reg Immunol. 1992. PMID: 1297406
-
Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.Cancer Res. 1992 Mar 15;52(6):1386-92. Cancer Res. 1992. PMID: 1531782
Cited by
-
The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.Br J Cancer. 1996 Jul;74(1):6-15. doi: 10.1038/bjc.1996.308. Br J Cancer. 1996. PMID: 8679459 Free PMC article.
-
Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model.Ann Surg. 2000 May;231(5):762-71. doi: 10.1097/00000658-200005000-00017. Ann Surg. 2000. PMID: 10767798 Free PMC article.
-
Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.J Exp Med. 1996 Feb 1;183(2):439-49. doi: 10.1084/jem.183.2.439. J Exp Med. 1996. PMID: 8627157 Free PMC article.
-
Strategies for cytokine utilisation in tumor therapy.Med Oncol Tumor Pharmacother. 1993;10(1-2):53-9. doi: 10.1007/BF02987769. Med Oncol Tumor Pharmacother. 1993. PMID: 8258996 Review.
-
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404. doi: 10.1073/pnas.93.19.10399. Proc Natl Acad Sci U S A. 1996. PMID: 8816812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources